Sagent Pharmaceuticals, Inc. 4
4 · Sagent Pharmaceuticals, Inc. · Filed Feb 24, 2014
Insider Transaction Report
Form 4
Logerfo Michael
Chief Legal Officer
Transactions
- Exercise/Conversion
Common Stock
2014-02-20$4.23/sh+20,000$84,600→ 39,957 total - Sale
Common Stock
2014-02-20$21.78/sh−3,894$84,811→ 36,063 total - Tax Payment
Common Stock
2014-02-21$21.84/sh−590$12,886→ 35,473 total - Sale
Common Stock
2014-02-20$22.05/sh−4,638$102,268→ 19,957 total - Tax Payment
Common Stock
2014-02-22$21.75/sh−441$9,592→ 35,032 total - Exercise/Conversion
Stock Option to Buy
2014-02-20−20,000→ 0 totalExercise: $4.23Exp: 2018-08-15→ Common Stock (20,000 underlying)
Holdings
- 1,000(indirect: See Footnote)
Common Stock
Footnotes (3)
- [F1]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $21.75 to $22.01, inclusive.
- [F2]Shares held by a member of Mr. Logerfo's immediate family sharing the same household. Mr. Logerfo disclaims beneficial ownership of such shares.
- [F3]Stock option granted on August 15, 2008 and vests 25% per year over four years.